RICHMOND, Va.--(BUSINESS WIRE)--Commonwealth Biotechnologies, Inc. (NASDAQ SC: CBTE), a life sciences contract research organization and biotechnology company (“CBI”), today announced that as of July 22, 2009, it has entered into definitive agreements with Biosignal Ltd, an Australian biotechnology company (“Biosignal”), pursuant to which Biosignal completed a $2,600,000 investment in CBI and agreed to assign its intellectual property related to Biosignal’s biofilm technology. The biofilm technology is based around a family of natural products which disrupt bacterial colonization and thereby inhibit growth. Such biofilm disrupters are expected to be commercialized to support a variety of medical and industrial applications.
